Sagard's healthcare royalty platform acquires Rubraca stake
Sagard Healthcare Royalty Partners (SHRP) has acquired a portion of a royalty interest in novel cancer drug Rubraca for US$31 million in cash. The seller is the U.K.-based University of Newcastle upon Tyne, which developed Rubraca in partnership with Cancer Research UK’s Cancer Research Technology Ltd and Pfizer Inc. Rubraca treats adults with ovarian cancer, fallopian tube or primary peritoneal cancer whose cancer has come back and are in response to a platinum-based chemotherapy, as well as other conditions. The investment is the first made by SHRP, launched this year by Sagard Holdings, an affiliate of Canada’s Power Corp.
1 April 2019•6 mins read
